Program
lurasidone
Also written as “Lurasidone”, “Lurasidone HCl” and “SM-13496”.
Its studies are mostly in Schizophrenia · Bipolar Disorder · Depressive Disorder, Major · Depression · Urinary Tract Infections, led by 4 companies.
Drug pageLurasidone: every studyAll 66 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sumitomo Pharmaits history only | 480 open or running | phase 4since Aug 7, 2021 | Aug 16, 2002 | none ahead |
| Bukwang Pharmaceutical | 21 open or running | phase 3since Mar 8, 2018 | Mar 8, 2018 | Oct 2027phase 3 · NCT07781293 |
| NeuroRxits history only | 11 open or running | phase 2since Nov 7, 2023 | Nov 7, 2023 | none ahead |
| Standard Chem. & Pharm.its history only | 10 open or running | phase 4since Dec 20, 2017 | Dec 20, 2017 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Bukwang Pharmaceutical only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 8, 2018First study: phase 3 study in SchizophreniaFirst studyNCT03465787 · 210 enrolled · Korea, Republic of
- Aug 6, 2026Phase 3 study in Depressive Disorder, MajorNCT07781293 · 364 planned
Ahead
- Oct 2027Primary completion: phase 3 study in Depressive Disorder, MajorNCT07781293
TargetBeta
“Serotonin 2a (5-HT2a) receptor antagonist; Dopamine D2 receptor antagonist”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Aripiprazolerule | Otsuka | phase 4 | 131 |
| Risperidonerule | Johnson & Johnson | phase 4 | 111 |
| paliperidonerule | Johnson & Johnson | phase 4 | 106 |
| Olanzapinerule | Eli Lilly | phase 4 | 76 |
| brexpiprazolerule | Otsuka | phase 4 | 70 |
| iloperidonerule | Vanda Pharmaceuticals | phase 4 | 15 |
| lumateperonerule | Johnson & Johnson | phase 3 | 25 |
Studies
All 2 Bukwang Pharmaceutical leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07781293Depressive Disorder, Major | 3 | Not yet recruiting | Oct 2027 | 364 |
| NCT03465787Schizophrenia · Korea, Republic of | 3 | Completed | Oct 26, 2022 | 210 |
How it is read
Names in the registry
- “Lurasidone”, 22 entries
- “Lurasidone HCl”, 10 entries
- “SM-13496”, 4 entries
- “Lurasidone 40 mg”, 3 entries
- “lurasidone”, 3 entries
Conditions, from the studies’ own filings
- Schizophrenia, 33 studies
- Bipolar Disorder, 7 studies
- Depressive Disorder, Major, 3 studies
- Depression, 2 studies
- Urinary Tract Infections, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.